Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Mochida Pharmaceutical Company, Ltd."
Count: 18
Selected: 0
NCT IDTitle
NCT04239950Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
NCT03350386Drug-drug Interaction Study of FYU-981 and Oxaprozin
NCT04345471A Study of MD-120 in Patients With Depression
NCT03375632Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
NCT03372200Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03306667Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
NCT03350373Clinical Pharmacology of FYU-981 (Final Formulation)
NCT04221217Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
NCT03693131Efficacy of MND-2119 in Participants With Hypertriglyceridemia
NCT02052895Utility of Presepsin in Distinguishing Between Sepsis and SIRS
NCT01154985Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
NCT00960180Study Evaluating Single Ascending Doses of MR1817
NCT03006445Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03100318Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02901366Mass Balance Study of FYU-981
NCT02746380A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT02357069A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00231738Protective Effect of EPA on Cardiovascular Events